SCHEMBL23964226

SCHEMBL23964226

CC(=O)Nc1ccc2[nH]c(CN3CCN(c4ccncc4)CC3)cc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.47
DRD4 P21917 5/20 0.47
DRD3 P35462 5/20 0.47
HTR1A P08908 1/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45
ADRA2C P18825 1/20 0.45
OPRK1 P41145 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
HTT P42858 1/20 0.45
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
KDM4E B2RXH2 3/20 0.43
ALDH1A1 P00352 3/20 0.43
MMP13 P45452 2/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041347 1.00 DRD2 (0.47) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL23964161 0.86 MAPT (0.52) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL30041863 0.84 DRD2 (0.47) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL23964263 0.84 DRD2 (0.47) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL25202850 0.82 PDGFRB (0.47) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL23964250 0.81 DRD2 (0.53) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL30042174 0.81 DRD2 (0.51) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL23932585 0.81 DRD2 (0.51) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL23964260 0.80 DRD4 (0.54) DRD2DRD4DRD3HTR1AADRA2A
SCHEMBL30041383 0.78 DRD4 (0.47) DRD2DRD4DRD3HTR1AADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 DRD2 4780/4885DRD4 4746/4885DRD3 4747/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.